DE602006015963D1 - Immunstimulatorisches verfahren - Google Patents

Immunstimulatorisches verfahren

Info

Publication number
DE602006015963D1
DE602006015963D1 DE602006015963T DE602006015963T DE602006015963D1 DE 602006015963 D1 DE602006015963 D1 DE 602006015963D1 DE 602006015963 T DE602006015963 T DE 602006015963T DE 602006015963 T DE602006015963 T DE 602006015963T DE 602006015963 D1 DE602006015963 D1 DE 602006015963D1
Authority
DE
Germany
Prior art keywords
immunostimulative
procedure
oligonucleotide
steroid
pharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015963T
Other languages
German (de)
English (en)
Inventor
Robert Loefberg
Stein Oliver Von
Arezou Zargari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Index Pharmaceuticals AB
Original Assignee
Index Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals AB filed Critical Index Pharmaceuticals AB
Publication of DE602006015963D1 publication Critical patent/DE602006015963D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE602006015963T 2005-07-01 2006-06-29 Immunstimulatorisches verfahren Active DE602006015963D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69617305P 2005-07-01 2005-07-01
PCT/SE2006/050229 WO2007004977A1 (en) 2005-07-01 2006-06-29 Immunostimulatory method

Publications (1)

Publication Number Publication Date
DE602006015963D1 true DE602006015963D1 (de) 2010-09-16

Family

ID=37604739

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015963T Active DE602006015963D1 (de) 2005-07-01 2006-06-29 Immunstimulatorisches verfahren

Country Status (14)

Country Link
US (2) US8258107B2 (ja)
EP (3) EP1901759B1 (ja)
JP (3) JP5074392B2 (ja)
AT (1) ATE476193T1 (ja)
AU (1) AU2006266503B2 (ja)
CA (1) CA2612162C (ja)
CY (1) CY1114965T1 (ja)
DE (1) DE602006015963D1 (ja)
DK (2) DK2269622T3 (ja)
ES (3) ES2349617T3 (ja)
PL (2) PL2380584T3 (ja)
PT (1) PT2269622E (ja)
SI (2) SI2380584T1 (ja)
WO (1) WO2007004977A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148341B2 (en) * 2005-07-01 2012-04-03 Index Pharmaceuticals Ab Method for modulating responsiveness to steroids
ES2349617T3 (es) * 2005-07-01 2011-01-07 Index Pharmaceuticals Ab Método inmunoestimulante.
JP2009513629A (ja) 2005-10-28 2009-04-02 インデックス・ファーマシューティカルズ・アクチエボラーグ 炎症性疾患を予防、処置、および/または緩和する組成物および方法
RU2010112771A (ru) * 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
AU2008339090A1 (en) * 2007-12-14 2009-06-25 Index Pharmaceuticals Ab Method for predicting the response to a therapy
CA2728276A1 (en) * 2008-06-18 2009-12-23 Index Pharmaceuticals Ab Combination therapies against cancer
AU2009311753B2 (en) * 2008-11-04 2015-01-15 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
KR102028784B1 (ko) 2012-05-16 2019-10-04 트랜슬레이트 바이오 인코포레이티드 유전자 발현을 조절하기 위한 조성물 및 방법
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707500D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy
GB201807312D0 (en) * 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
TW244371B (ja) 1992-07-23 1995-04-01 Tri Clover Inc
CA2105595A1 (en) 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US20030078223A1 (en) 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
SE9602300D0 (sv) 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING NON-METHYLATED CpG DINUCLEOTIDES IN THE TREATMENT OF LIPOPOLYSACCHARIDE-ASSOCIATED ILLNESSES
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1077708A1 (en) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
EP1078053B1 (en) 1998-05-14 2005-09-28 Coley Pharmaceutical GmbH METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
EP1077722B1 (en) 1998-05-22 2006-08-09 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション CpGオリゴヌクレオチドの立体異性体および関連する方法
DK1221955T3 (da) 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
EP1688147A1 (en) 1999-09-27 2006-08-09 Coley Pharmaceutical Group, Inc. Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
JP2003510290A (ja) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激核酸誘導インターフェロンに関する方法
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US6649341B1 (en) 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
SI1296714T1 (sl) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
CA2419894A1 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
US6294382B1 (en) 2000-11-27 2001-09-25 Isis Pharmaceuticals, Inc. Antisense modulation of SRC-1 expression
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
JP2002257827A (ja) 2001-03-01 2002-09-11 Jenokkusu Soyaku Kenkyusho:Kk ステロイド応答性の検査方法
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
WO2003031573A2 (en) 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
EP1434602B1 (en) 2001-10-06 2014-12-17 Merial Limited CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D
JP2005526497A (ja) 2002-02-04 2005-09-08 ビオミラ,インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
IL164354A0 (en) 2002-04-04 2005-12-18 Coley Pharm Gmbh Immunostimulatory g,u-containing oligoribonucleotides
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
KR101309501B1 (ko) 2002-12-23 2013-09-24 다이나박스 테크놀로지 코퍼레이션 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법
US7625872B2 (en) 2002-12-23 2009-12-01 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
MXPA05007652A (es) 2003-01-16 2006-02-22 Hybridon Inc Modulacion de propiedades inmunoestimulantes de compuestos basados en oligonucleotido mediante la utilizacion de dinucleotidos inmunoestimulantes modificados.
CN100560719C (zh) 2003-03-26 2009-11-18 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
WO2004087203A2 (en) 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US7569554B2 (en) 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US20050158325A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
CA2555105A1 (en) 2004-02-20 2005-09-09 Hybridon, Inc. Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
EP2901856B1 (en) 2004-06-15 2017-08-09 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
NZ553581A (en) 2004-09-01 2011-04-29 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
KR20080008350A (ko) 2005-04-08 2008-01-23 콜레이 파마시티컬 그룹, 인코포레이티드 감염성 질환에 의해 악화된 천식의 치료 방법
ES2349617T3 (es) * 2005-07-01 2011-01-07 Index Pharmaceuticals Ab Método inmunoestimulante.
US8148341B2 (en) * 2005-07-01 2012-04-03 Index Pharmaceuticals Ab Method for modulating responsiveness to steroids

Also Published As

Publication number Publication date
ATE476193T1 (de) 2010-08-15
EP2269622A1 (en) 2011-01-05
EP2380584B1 (en) 2013-10-16
US8258107B2 (en) 2012-09-04
PL2380584T3 (pl) 2014-03-31
US20120277293A1 (en) 2012-11-01
CA2612162C (en) 2016-05-17
DK2269622T3 (en) 2014-03-24
WO2007004977A1 (en) 2007-01-11
CY1114965T1 (el) 2016-12-14
CA2612162A1 (en) 2007-01-11
EP2269622B1 (en) 2013-12-25
ES2450593T3 (es) 2014-03-25
JP5074392B2 (ja) 2012-11-14
AU2006266503B2 (en) 2011-12-08
JP2008544983A (ja) 2008-12-11
US8592390B2 (en) 2013-11-26
ES2349617T3 (es) 2011-01-07
SI2380584T1 (sl) 2014-04-30
ES2442090T3 (es) 2014-02-10
DK2380584T3 (da) 2014-01-20
AU2006266503A1 (en) 2007-01-11
JP5945176B2 (ja) 2016-07-05
SI2269622T1 (sl) 2014-05-30
PT2269622E (pt) 2014-03-20
JP2012232989A (ja) 2012-11-29
EP1901759B1 (en) 2010-08-04
EP2380584A1 (en) 2011-10-26
PL2269622T3 (pl) 2014-05-30
EP1901759A1 (en) 2008-03-26
US20100234449A1 (en) 2010-09-16
JP2012232988A (ja) 2012-11-29

Similar Documents

Publication Publication Date Title
DE602006015963D1 (de) Immunstimulatorisches verfahren
ATE439135T1 (de) Modulierung der reaktion auf steroide
CY1114979T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
EA200702616A1 (ru) Дозированная форма для перорального применения
GT200500360A (es) Compuestos organicos
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EP1855679A4 (en) INHIBITORS OF AMINOMETHYL BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE
DK1864668T3 (da) Anvendelse af prodrug til okulær, intravitreal administration
EA200601884A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
UY30675A1 (es) Metodos para el tratamiento de la depresion
ATE474574T1 (de) Imidazoazephinonverbindungen
TW200640467A (en) Compounds and uses thereof
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
HN2007000505A (es) Analogos de pirazol
RU2005128615A (ru) Средство для лечения заболеваний пародонта